{"id":70803,"date":"2026-07-28T18:37:26","date_gmt":"2026-07-28T10:37:26","guid":{"rendered":"https:\/\/flcube.com\/?p=70803"},"modified":"2026-07-28T18:37:27","modified_gmt":"2026-07-28T10:37:27","slug":"fosun-pharmas-dm1001-receives-nmpa-clearance-for-parkinsons-disease-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70803","title":{"rendered":"Fosun Pharma&#8217;s DM1001 Receives NMPA Clearance for Parkinson&#8217;s Disease Clinical Trials"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shanghai Fosun Pharmaceutical (Group) Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/600196:SHA\">SHA: 600196<\/a>, <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2196:HKG\">HKG: 2196<\/a>) announced that <strong>DM1001<\/strong>, a chemical drug developed by its subsidiary <strong>Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd.<\/strong> (&#8220;Fosun Wanbang&#8221;), has received approval from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> to initiate clinical trials for the treatment of <strong>signs and symptoms of idiopathic Parkinson&#8217;s disease in adults<\/strong>. The company plans to commence <strong>Phase I clinical trials<\/strong> in China once preparatory conditions are fulfilled.<\/p>\n\n\n\n<h2 id=\"h-development-overview\" class=\"wp-block-heading\">Development Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parent Company<\/strong><\/td><td>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd.<\/td><\/tr><tr><td><strong>Drug Designation<\/strong><\/td><td>DM1001 (chemical drug)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Signs and symptoms of idiopathic Parkinson&#8217;s disease in adults<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase I (planned)<\/td><\/tr><tr><td><strong>Regulatory Milestone<\/strong><\/td><td>NMPA clinical trial approval<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>28 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-therapeutic-context-parkinson-s-disease\" class=\"wp-block-heading\">Therapeutic Context \u2013 Parkinson&#8217;s Disease<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Burden:<\/strong> Parkinson&#8217;s disease affects approximately <strong>3 million people in China<\/strong>, with incidence rising due to aging population demographics<\/li>\n\n\n\n<li><strong>Current Treatment Gaps:<\/strong> Existing therapies primarily address motor symptoms but have limited impact on disease progression and non-motor manifestations<\/li>\n\n\n\n<li><strong>Unmet Needs:<\/strong> Novel agents targeting both symptomatic relief and potential disease modification remain high priority for patients and clinicians<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> China&#8217;s Parkinson&#8217;s therapeutics market projected to reach <strong>\u00a55 billion ($700 million)<\/strong> by 2030, driven by increasing diagnosis rates and treatment accessibility<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-development-strategy\" class=\"wp-block-heading\">Development Strategy<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Objective<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase I<\/strong><\/td><td>Safety, tolerability, and pharmacokinetics in healthy volunteers or patients<\/td><td>Upon condition fulfillment<\/td><\/tr><tr><td><strong>Future Phases<\/strong><\/td><td>Efficacy assessment in Parkinson&#8217;s disease patients<\/td><td>Not disclosed<\/td><\/tr><tr><td><strong>Regulatory Pathway<\/strong><\/td><td>Full development program under NMPA oversight<\/td><td>Standard approval pathway anticipated<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Fosun Wanbang&#8217;s approach leverages the parent company&#8217;s extensive clinical development infrastructure and regulatory expertise in China&#8217;s pharmaceutical landscape.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fosun Pharma Portfolio Expansion:<\/strong> Entry into neurodegenerative disorders represents strategic diversification beyond Fosun&#8217;s traditional strengths in oncology, immunology, and anti-infectives<\/li>\n\n\n\n<li><strong>China Innovation Focus:<\/strong> Part of broader trend of Chinese pharmaceutical companies addressing high-burden neurological conditions with domestically developed therapeutics<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Limited innovative Parkinson&#8217;s therapies developed by Chinese companies creates potential first-mover advantages in specific therapeutic approaches<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Successful development could position DM1001 for international partnerships, particularly given the universal nature of Parkinson&#8217;s disease burden<\/li>\n\n\n\n<li><strong>Healthcare System Alignment:<\/strong> Addresses China&#8217;s national priorities for developing treatments for age-related chronic conditions affecting quality of life<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory pathways, and commercial potential for DM1001. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600196_20260725_SZND.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600196_20260725_SZND.\"><\/object><a id=\"wp-block-file--media-eb5168e3-6312-4cfa-8bc4-a11557c170ea\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600196_20260725_SZND.pdf\">600196_20260725_SZND<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/600196_20260725_SZND.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-eb5168e3-6312-4cfa-8bc4-a11557c170ea\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that DM1001, a chemical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,159,3834,893,892],"class_list":["post-70803","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-fosun-pharmaceutical","tag-fosun-wanbang-pharmaceutical","tag-hkg-2196","tag-sha-600196"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Fosun Pharma&#039;s DM1001 Receives NMPA Clearance for Parkinson&#039;s Disease Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that DM1001, a chemical drug developed by its subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. (&quot;Fosun Wanbang&quot;), has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of signs and symptoms of idiopathic Parkinson&#039;s disease in adults. The company plans to commence Phase I clinical trials in China once preparatory conditions are fulfilled.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70803\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fosun Pharma&#039;s DM1001 Receives NMPA Clearance for Parkinson&#039;s Disease Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that DM1001, a chemical drug developed by its subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. (&quot;Fosun Wanbang&quot;), has received approval from China&#039;s National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of signs and symptoms of idiopathic Parkinson&#039;s disease in adults. The company plans to commence Phase I clinical trials in China once preparatory conditions are fulfilled.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70803\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-28T10:37:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-28T10:37:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70803#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70803\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Fosun Pharma&#8217;s DM1001 Receives NMPA Clearance for Parkinson&#8217;s Disease Clinical Trials\",\"datePublished\":\"2026-07-28T10:37:26+00:00\",\"dateModified\":\"2026-07-28T10:37:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70803\"},\"wordCount\":428,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Fosun Pharmaceutical\",\"Fosun Wanbang Pharmaceutical\",\"HKG: 2196\",\"SHA: 600196\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70803#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70803\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70803\",\"name\":\"Fosun Pharma's DM1001 Receives NMPA Clearance for Parkinson's Disease Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-28T10:37:26+00:00\",\"dateModified\":\"2026-07-28T10:37:27+00:00\",\"description\":\"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that DM1001, a chemical drug developed by its subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. (\\\"Fosun Wanbang\\\"), has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of signs and symptoms of idiopathic Parkinson's disease in adults. The company plans to commence Phase I clinical trials in China once preparatory conditions are fulfilled.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70803#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70803\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70803#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fosun Pharma&#8217;s DM1001 Receives NMPA Clearance for Parkinson&#8217;s Disease Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Fosun Pharma's DM1001 Receives NMPA Clearance for Parkinson's Disease Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that DM1001, a chemical drug developed by its subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. (\"Fosun Wanbang\"), has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of signs and symptoms of idiopathic Parkinson's disease in adults. The company plans to commence Phase I clinical trials in China once preparatory conditions are fulfilled.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70803","og_locale":"en_US","og_type":"article","og_title":"Fosun Pharma's DM1001 Receives NMPA Clearance for Parkinson's Disease Clinical Trials","og_description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that DM1001, a chemical drug developed by its subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. (\"Fosun Wanbang\"), has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of signs and symptoms of idiopathic Parkinson's disease in adults. The company plans to commence Phase I clinical trials in China once preparatory conditions are fulfilled.","og_url":"https:\/\/flcube.com\/?p=70803","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-28T10:37:26+00:00","article_modified_time":"2026-07-28T10:37:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70803#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70803"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Fosun Pharma&#8217;s DM1001 Receives NMPA Clearance for Parkinson&#8217;s Disease Clinical Trials","datePublished":"2026-07-28T10:37:26+00:00","dateModified":"2026-07-28T10:37:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70803"},"wordCount":428,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Fosun Pharmaceutical","Fosun Wanbang Pharmaceutical","HKG: 2196","SHA: 600196"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70803#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70803","url":"https:\/\/flcube.com\/?p=70803","name":"Fosun Pharma's DM1001 Receives NMPA Clearance for Parkinson's Disease Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-28T10:37:26+00:00","dateModified":"2026-07-28T10:37:27+00:00","description":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that DM1001, a chemical drug developed by its subsidiary Fosun Wanbang (Jiangsu) Pharmaceutical Group Co., Ltd. (\"Fosun Wanbang\"), has received approval from China's National Medical Products Administration (NMPA) to initiate clinical trials for the treatment of signs and symptoms of idiopathic Parkinson's disease in adults. The company plans to commence Phase I clinical trials in China once preparatory conditions are fulfilled.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70803#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70803"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70803#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Fosun Pharma&#8217;s DM1001 Receives NMPA Clearance for Parkinson&#8217;s Disease Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70803","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70803"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70803\/revisions"}],"predecessor-version":[{"id":70805,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70803\/revisions\/70805"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}